Tharimmune, Inc. announced on July 23, 2025, the pricing of a registered direct public offering, expecting to raise gross proceeds of approximately $1.74 million. This offering is intended to provide capital for the company's development programs.
The offering includes 414,331 shares of common stock and 559,910 pre-funded warrants to acquire shares of common stock. Additionally, 974,241 warrants to acquire shares of common stock at an exercise price of $1.66 per share were part of the offering.
The securities were priced at $1.786 per unit, comprised of one share of common stock or a pre-funded warrant and a common warrant. This capital raise is crucial for Tharimmune to sustain its operations and advance its clinical-stage pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.